1. Pink Sheet
  2. >>Market Access

Capping Off The Rebate Debate: Will 2019 Price Push End With Co-Pay Cap?

 
• By Michael McCaughan

The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.

Smooth Focus,There is no money left in the bag, only the credit card that is used to the full limit and cannot be used to buy the necessary items because of wrong money management
Seniors might find more money in their wallets if Congress can agree to a co-pay cap for Part D.

A US House Energy & Commence/Health Subcommittee hearing on prescription drug coverage under Medicare offered a public reminder that there remains strong bipartisan support for capping out of pocket costs for Part D beneficiaries.

While the 30 April hearing, “Prescription Drug Coverage in the Medicare Program,” was broader in scope than what seniors pay at the pharmacy counter, the need for a fixed limit on beneficiary spending was a recurring theme. E&C Chair Frank Pallone, D-NJ, Ranking Member Greg Walden, R-OR, Subcommittee Chair Anna Eshoo, D-CA, and Rep

More from Pricing Debate

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.

340B Not Designed To Pass Savings Directly To Patients, Hospitals Tell Senate Committee

 
• By Cathy Kelly

Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.

More from Market Access

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.